



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	129.19
Trade Time:	4:00 PM ET Aug 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	96.93 - 139.00
Volume	7

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Aug 1, 2017*  
[FDA Grants Approval of IDHIFA® the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation](#)

*Jul 28, 2017*  
[Celgene Corporation to Webcast at Upcoming Investor Conference](#)

*Jul 27, 2017*  
[Celgene Reports Second Quarter 2017 Operating and Financial Results](#)

*Jul 25, 2017*  
[Celgene Corporation Announces Settlement of Civil Litigation](#)

*Jul 5, 2017*  
[Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers](#)

## Financials [\[ View all \]](#)

*Feb 10, 2017*  
[Annual Report \(10-K\)](#)

*Apr 27, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)

*Apr 27, 2017*  
[Quarterly Report \(10-Q\)](#)

*Oct 27, 2016*  
[Quarterly Report \(10-Q\)](#)